Mes choix et mouvements sont basés sur l'analyse technique des graphiques,merci pour votre attention et fidélité,le succès de chaque individu dépend de son fond, le dévouement,le désir et la motivation. Soutenir trades actions biotechs en faisant un Don via le bouton Paypal(totalement sécurisé) merci pour vôtre contribution.
Articles les plus consultés
-
francis 13 Version sans publicité Marchés Actualités Analyses Crypto Fonds Graphiques Technique Brokers Outils Portefe...
-
6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium 14.95 + 39.07% 0,60K Mondialisation de l'Inde. 0,4800 + 18,52% 1,80K...
-
Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation 51.30 + 10,73% 58.90K Staples Inc 9.25 + 6,81% 12,31K Delcat...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath 0.1230 + 24,24% 196,67K Neos Therapeutics I. 10.50 +16.67% 34.36K Enpha...
-
Citoyens_Français @citoyenneFrance 8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In 5.32 + 32,34% 38.64K Enphase Energy Inc 0,938 + 17,57% 10,37K Delca...
-
28 juin 2017 Nom du médicament et numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
-
Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc 1,3900 +25,23% 3,55K Alibaba 139,95 +11,35% 1,40M MoSys...
samedi 30 juin 2018
vendredi 29 juin 2018
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) | Business Wire: ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimav
jeudi 28 juin 2018
22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire
22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire: (美国商业资讯) -- 22nd Century Group, Inc. (NYSE American: XXII) 是一家植物生物技术公司,也是烟草减害和极低尼古丁烟草领域的领导者。公司今天宣布,已从北卡罗莱纳州立大学(NCSU)获得若干种尼古丁含量极低的烤烟和白肋烟植物品系的排他性授权。上述新植
PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q
PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q: PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors
mardi 26 juin 2018
recommandations
26/06/2018 | 08:56
PARIS, 26 juin (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés mardi à Paris:
* RENAULT - Morgan Stanley a relevé sa recommandation à "pondération en ligne"
contre "sous-pondérer", avec un objectif de cours de 88 euros.
* DASSAULT SYSTEMES - UBS, à "vendre" sur la valeur, a relevé son objectif de
cours à 112 euros contre 87,50 euros.
* ARKEMA - Barclays, à "surpondérer" sur la valeur, a abaissé son objectif de cours
à 121 euros contre 128 euros.
* ERYTECH PHARMA - Jefferies, à l'achat sur la valeur, a abaissé son objectif de
cours à 36 euros contre 39 euros.
lundi 25 juin 2018
dimanche 24 juin 2018
Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire
Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System
mercredi 20 juin 2018
22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire
22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA | Business Wire: 22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA; Details available at www.clinicaltrials.gov
mardi 19 juin 2018
PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire
PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始 | Business Wire: (ビジネスワイヤ) -- PHCホールディングス株式会社(本社:東京都港区)の100%子会社である、PHC株式会社(以下「PHC」)は、このたび、保険薬局用電子薬歴システム「PharnesV-MX」を発売しましたので、お知らせします。 PharnesV-MXは、薬剤師の業務改善を目指した新しい電子薬
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S. | Business Wire: ITM announced today that the U.S. FDA has accepted the Investigational New Drug Application to advance its radiopharmaceutical to a phase III trial
Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire
Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions | Business Wire: Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste
lundi 18 juin 2018
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer | Business Wire: ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that t
BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire
BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018 | Business Wire: BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve
dimanche 17 juin 2018
vendredi 15 juin 2018
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association | Business Wire: Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCE
jeudi 14 juin 2018
Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire
Global Healthcare Contract Research and Manufacturing Outsourcing Market to Post a CAGR of 12% | Technavio | Business Wire: The global healthcare contract research and manufacturing outsourcing market is set to post a CAGR of almost 12% until 2022, according to Technavio.
mercredi 13 juin 2018
FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire
FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay | Business Wire: Gold Standard Diagnostics, Corp. today announced the U.S. Food and Drug Administration issued a 510(k) clearance for its Borrelia burgdorferi IgG/IgM
ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire
ExThera Medical gibt Abschluss von Studie zur Bewertung der Sicherheit des Blutfilters Seraph® 100 für die Registrierung der CE-Kennzeichnung bekannt | Business Wire: Die ExThera Medical Corporation, ein Entwickler von Therapien für die Entfernung von Bakterien und Viren aus dem Blut, hat heute den Abschluss ihrer S
mardi 12 juin 2018
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Business Wire: Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease throug
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) | Business Wire: FDA Approves Merck’s KEYTRUDA for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1
Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire
Los resultados del estudio fase III OPTIMISMM presentados en ASCO 2018 mostraron que el triplete PVd mejoraba la SLP en líneas precoces del mieloma múltiple recidivante o refractario | Business Wire: Celgene Corporation (NASDAQ: CELG) anunció hoy los resultados del estudio OPTIMISMM, un ensayo clínico fase III, internacional, aleatorizado, abierto,
ExThera Medical annonce la conclusion de l'essai d'homologation du marquage CE visant à évaluer la sécurité d'emploi du filtre à sang Seraph® 100 | Business Wire
ExThera Medical annonce la conclusion de l'essai d'homologation du marquage CE visant à évaluer la sécurité d'emploi du filtre à sang Seraph® 100 | Business Wire: ExThera Medical Corporation, qui développe des traitements visant à éliminer les bactéries et virus du sang, a annoncé aujourd'hui la conclusion de l'
リヴァノヴァの無縫合大動脈心臓弁パーシバルが日本で承認される | Business Wire
リヴァノヴァの無縫合大動脈心臓弁パーシバルが日本で承認される | Business Wire: 市場をリードする医療技術企業のリヴァノヴァ(NASDAQ:LIVN)(「リヴァノヴァ」または「当社」)は本日、大動脈弁疾患を治療するための当社の無縫合大動脈心臓弁Perceval®(パーシバル)を日本の厚生労働省が承認したと発表しました。 リヴァノヴァ株式会社の川名範明社長は、次のように述べています
Agilent Enables CISH on Dako Omnis | Business Wire
Agilent Enables CISH on Dako Omnis | Business Wire: Agilent Technologies Inc. (NYSE: A) today announced the release of a new accessory kit that enables the company’s Dako Omnis system to analyze tissue
lundi 11 juin 2018
Riassunto: Pharnext presenterà i dati scientifici più aggiornati sui due suoi prodotti principali a diversi congressi scientifici internazionali | Business Wire
Riassunto: Pharnext presenterà i dati scientifici più aggiornati sui due suoi prodotti principali a diversi congressi scientifici internazionali | Business Wire: Notizie normative: Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), società biofarmaceutica impegnata in un approccio pionieristico allo sviluppo di
Los resultados de fase 2 de erdafitinib son prometedores para el tratamiento del cáncer urotelial metastásico | Business Wire
Los resultados de fase 2 de erdafitinib son prometedores para el tratamiento del cáncer urotelial metastásico | Business Wire: Las empresas farmacéuticas Janssen de Johnson & Johnson han anunciado hoy los resultados de un estudio de fase 2, que muestran que el tratamiento
vendredi 8 juin 2018
BRITVIC
Dans une note de recherche intitulée "Starting to fizz", le bureau d'analyses allemand a indiqué qu'il avait également relevé son objectif de cours de 725 pence à 900 pence.
Britvic possède un portefeuille de marques, dont Tango, Teisseire, Fruité, Maguary et DaFruta, et produit également des boissons comme Pepsi, 7UP, SoBe et Mountain Dew en Angleterre et en Irlande suite à des accords exclusifs avec PepsiCo.
Britvic possède un portefeuille de marques, dont Tango, Teisseire, Fruité, Maguary et DaFruta, et produit également des boissons comme Pepsi, 7UP, SoBe et Mountain Dew en Angleterre et en Irlande suite à des accords exclusifs avec PepsiCo.
jeudi 7 juin 2018
Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions
Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions
mercredi 6 juin 2018
jeudi 31 mai 2018
jeudi 24 mai 2018
mercredi 23 mai 2018
ResMed-Studien zeigen, dass Fernüberwachung und automatisierte Nachversorgung Therapietreue bei PAP-Therapie verbessern | Business Wire
ResMed-Studien zeigen, dass Fernüberwachung und automatisierte Nachversorgung Therapietreue bei PAP-Therapie verbessern | Business Wire: Ferngesteuerte Patientenüberwachungs- und Nachschubprogramme verbessern nachweislich die Therapietreue von Patienten mit positivem Atemwegsdruck (PAP)
Allscripts Sunrise™ powers The Dudley Group NHS Foundation Trust to transform delivery of care
Allscripts Sunrise™ powers The Dudley Group NHS Foundation Trust to transform delivery of care: One of the country’s largest teaching hospitals leads the way in connecting the health economy in U.K. and provides tools to increase efficiency in an era of ever greater demand
Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease | Business Wire
Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease | Business Wire: Tiotropium/olodaterol Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease
lundi 21 mai 2018
Janssen presentará nuevos datos sobre cánceres urotelial, hematológico y de próstata en la ASCO 2018, incluidas las selecciones de lo mejor de la ASCO | Business Wire
Janssen presentará nuevos datos sobre cánceres urotelial, hematológico y de próstata en la ASCO 2018, incluidas las selecciones de lo mejor de la ASCO | Business Wire: Las empresas farmacéuticas Janssen de Johnson & Johnson han anunciado hoy que se presentarán 21 resúmenes patrocinados por la empresa en la Reunió
Dr. Martin T. Rothman devient Venture Partner de Sofinnova Partners | Business Wire
Dr. Martin T. Rothman devient Venture Partner de Sofinnova Partners | Business Wire: Sofinnova Partners appoints internationally renowned physician and entrepreneur, Dr. Martin T. Rothman, as Venture Partner.
UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDA | Business Wire
UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDA | Business Wire: UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today
samedi 19 mai 2018
Takeda présentera son vaste portefeuille en oncologie et ses données préliminaires lors de l'assemblée de l'American Society of Clinical Oncology (ASCO) et du congrès de l'European Hematology Association (EHA) | Business Wire
Takeda présentera son vaste portefeuille en oncologie et ses données préliminaires lors de l'assemblée de l'American Society of Clinical Oncology (ASCO) et du congrès de l'European Hematology Association (EHA) | Business Wire: Takeda Pharmaceutical Company Limited (TSE: 4502) a annoncé aujourd'hui que la société présentera un total de 14 présentations sponsorisées par Takeda
vendredi 18 mai 2018
Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago | Business Wire
Oncodesign Announces Publication of an Abstract for the 54th ASCO Annual Meeting in Chicago | Business Wire: Regulatory News: ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical company specializing in precision medicine, announces the public
Cathryn Tames Receives the Rite Aid Foundation’s KIDCHAMPSM Award | Business Wire
Cathryn Tames Receives the Rite Aid Foundation’s KIDCHAMPSM Award | Business Wire: The Rite Aid Foundation announced today that Cathryn Tames, Executive Director of the Children’s Developmental Center in Richland, Washington, has bee
Resumen: BioClin Therapeutics, Inc. anuncia la presentación del póster de B-701 en la edición 2018 de la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) | Business Wire
Resumen: BioClin Therapeutics, Inc. anuncia la presentación del póster de B-701 en la edición 2018 de la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) | Business Wire: BioClin Therapeutics, Inc., una compañía dedicada al desarrollo de fármacos clínicos, ha anunciado hoy que los datos derivados de su estudio en curso
Samenvatting: Takeda belicht breed Oncologie-Portfolio en Pipeline Data tijdens de jaarlijkse bijeenkomsten van de American Society of Clinical Oncology (ASCO) en het congres van de European Hematology Association (EHA) | Business Wire
Samenvatting: Takeda belicht breed Oncologie-Portfolio en Pipeline Data tijdens de jaarlijkse bijeenkomsten van de American Society of Clinical Oncology (ASCO) en het congres van de European Hematology Association (EHA) | Business Wire: Takeda Pharmaceutical Company Limited (TSE: 4502) kondigde vandaag aan dat het bedrijf in totaal 14 door Takeda Oncology-gesponsorde presentaties zal
NeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate | Business Wire
NeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate | Business Wire: NeoTract Announces American Urological Association Recommendation of UroLift® System as a Standard of Care Option for Enlarged Prostate Treatment
jeudi 17 mai 2018
EURONEXT 457SX
|
|
Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting | Business Wire
Protalex Announces Presentation Highlighting PRTX-100 Phase 1b Clinical Data in Patients with Immune Thrombocytopenia at the European Hematology Association 23rd Annual Meeting | Business Wire: Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-lab
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2018 Annual Meeting | Business Wire
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2018 Annual Meeting | Business Wire: Flatiron Health today announced 11 abstracts accepted for presentation at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which
LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint | Business Wire
LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint | Business Wire: Pfizer Inc. (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution CV as adj
Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association: Oral and poster presentations highlight BPX-501 data in pediatric patients with PIDs and AML
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting | Business Wire
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting | Business Wire: Pierre Fabre with its partner Array BioPharma Inc. will present overall survival (OS) data from its late-stage candidates encorafenib, a BRAF inhibito
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma | Business Wire
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma | Business Wire: Exelixis, Inc. (Nasdaq:EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib)
mercredi 16 mai 2018
AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing | Business Wire
AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing | Business Wire: AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing
Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC | Business Wire
Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC | Business Wire: Viz.ai, an applied artificial intelligence healthcare co, to present expanded ALADIN and new ADVANCE data expanding its stroke pipeline at ESOC 2018
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions | Business Wire
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions | Business Wire: Celgene to Present New Clinical Data at ASCO 2018 highlighting the value of innovative research in key blood cancer and solid tumor disease areas
Minomic Completes Prospective Clinical Study Using MiCheck® to Assist in Diagnosis of Prostate Cancer | Business Wire
Minomic Completes Prospective Clinical Study Using MiCheck® to Assist in Diagnosis of Prostate Cancer | Business Wire: Minomic International Ltd announced the completion of its Prospective Clinical Trial of the company's novel prostate cancer diagnostic test, MiCheck®.
Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD | Business Wire
Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD | Business Wire: Vitrisa Therapeutics, Inc., a Company focused on developing a suite of platform technologies optimized for ocular therapeutics and an associated pipel
vôtre suivi ce jour merci
Entrée | Pages vues |
---|---|
France
|
381
|
Italie
|
182
|
États-Unis
|
25
|
Allemagne
|
9
|
Pologne
|
9
|
Ukraine
|
5
|
Algérie
|
4
|
Portugal
|
4
|
Irlande
|
2
|
Islande
|
2
|
merci pour vôtre suivi
Pages vues aujourd'hui
|
59
|
Pages vues hier
|
107
|
Pages vues le mois dernier
|
3 669
|
Historique global des pages vues
|
243 216
|
Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting | Business Wire
Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting | Business Wire: Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical devel
PharmaCyte Biotech Successfully Completes 29 Tests Conducted on Live Cells Used in Pancreatic Cancer Therapy | Business Wire
PharmaCyte Biotech Successfully Completes 29 Tests Conducted on Live Cells Used in Pancreatic Cancer Therapy | Business Wire: PharmaCyte Biotech announces successful completion of 29 tests conducted on live cells used in pancreatic cancer therapy.
Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E | Business Wire
Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E | Business Wire: Myonexus Therapeutics receives FDA Rare Pediatric Drug Designation for pioneering gene therapy treatment of limb girdle muscular dystrophy type 2E.
Scientist.com and Brain and Spine Institute’s Bioincubator, iPEPS, Launch Biotech Startup Competition for Companies Accelerating CNS Disease Research | Business Wire
Scientist.com and Brain and Spine Institute’s Bioincubator, iPEPS, Launch Biotech Startup Competition for Companies Accelerating CNS Disease Research | Business Wire: Scientist.com, the life science industry’s leading online marketplace for outsourced research, and The Brain and Spine Institute incubator, iPEPS-ICM,
vendredi 11 mai 2018
recommandations
Bourse de Paris : Le point sur les changements de recommandations à Paris
|
11/05/2018 | 07:55
PARIS, 11 mai (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés vendredi à Paris.
* SOLUTIONS 30 SE - Berenberg abaisse sa recommandation à "conserver" contre
"acheter" et relève l'objectif de cours à 42,50 euros contre 38,50 euros.
SAFE ORTHOPAEDICS SA - Midcap Partners entame son suivi avec une recomandation
"neutre" et un objectif de cours à 0,55%.
* AIR FRANCE-KLM - HSBC abaisse l'objectif de cours à 9,5 euros contre 13 euros.
jeudi 10 mai 2018
mercredi 9 mai 2018
mardi 8 mai 2018
Abeona Therapeutics Announces Upcoming Presentations
Abeona Therapeutics Announces Upcoming Presentations: Presentations at the American Society of Gene and Cell Therapy Conference and the International Investigative Dermatology Conference
lundi 7 mai 2018
Inscription à :
Articles (Atom)